{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:27:22Z","timestamp":1780676842318,"version":"3.54.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1097\/jcp.0b013e3181c9bfe6","type":"journal-article","created":{"date-parts":[[2010,1,7]],"date-time":"2010-01-07T06:08:48Z","timestamp":1262844528000},"page":"3-10","source":"Crossref","is-referenced-by-count":70,"title":["Neuroleptic-Induced Catatonia"],"prefix":"10.1097","volume":"30","author":[{"given":"Joseph W.Y.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210128","first-page":"48","article-title":"Catatonia: a review of a behavioral neurologic syndrome.","volume":"3","author":"Taylor","year":"1990","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"R3-2-20210128","first-page":"745","article-title":"An unusual complication following the use of trilafon in children.","volume":"9","author":"Berry","year":"1958","journal-title":"U S Armed Forces Med J"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1176\/ajp.115.12.1119","article-title":"Catatonic-like states following phenothiazine therapy.","volume":"115","author":"May","year":"1959","journal-title":"Am J Psychiatry"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1192\/bjp.121.6.599","article-title":"Mutism induced by phenothiazines.","volume":"121","author":"Behrman","year":"1972","journal-title":"Br J Psychiatry"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1192\/bjp.122.2.240-b","article-title":"Catatonia from fluphenazine.","volume":"122","author":"De","year":"1973","journal-title":"Br J Psychiatry"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archpsyc.1977.01770200085010","article-title":"Catatonic reactions to high-potency neuroleptic drugs.","volume":"34","author":"Gelenberg","year":"1977","journal-title":"Arch Gen Psychiatry"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-0028-1094618","article-title":"Reversal of neuroleptic-induced stupor by procyclidine: two case reports and their theoretical implications.","volume":"12","author":"Ungvari","year":"1979","journal-title":"Pharmakopsychiatr Neuropsychopharmakol"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1017\/S0007125000114072","article-title":"Neuroleptic-induced catatonic symptoms.","volume":"142","author":"Cremona-Barbaro","year":"1983","journal-title":"Br J Psychiatry"},{"key":"R10-2-20210128","first-page":"310","article-title":"Neuroleptic-induced catatonia: case report.","volume":"44","author":"Johnson","year":"1983","journal-title":"J Clin Psychiatry"},{"key":"R11-2-20210128","first-page":"581","article-title":"Neuroleptic-associated catatonic reaction.","volume":"2","author":"Dorevitch","year":"1983","journal-title":"Clin Pharm"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00004714-198312000-00002","article-title":"Intravenous lorazepam in neuroleptic-induced catatonia.","volume":"3","author":"Fricchione","year":"1983","journal-title":"J Clin Psychopharmacol"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2190\/LXD2-JTXJ-3LPQ-9PDN","article-title":"Neuroleptic malignant syndrome and neuroleptic-induced catatonia: differential diagnosis and treatment.","volume":"14","author":"Stoudemire","year":"1984","journal-title":"Int J Psychiatry Med"},{"key":"R14-2-20210128","first-page":"275","article-title":"Mental handicap, psychosis and thyrotoxicosis: a demonstration of the usefulness of an integrated community and hospital service.","volume":"29","author":"Mayer","year":"1985","journal-title":"J Ment Defic Res"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/j.1875-9114.1986.tb03475.x","article-title":"Neuroleptic-induced catatonia after abrupt withdrawal of amantadine during neuroleptic therapy.","volume":"6","author":"Brown","year":"1986","journal-title":"Pharmacotherapy"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00005053-198607000-00007","article-title":"Catatonic reaction to accidental haloperidol overdose: an unrecognized drug abuse risk.","volume":"174","author":"Hoffman","year":"1986","journal-title":"J Nerv Ment Dis"},{"issue":"7","key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/070674378803300712","article-title":"Drug-induced catatonia.","volume":"33","author":"Herrmann","year":"1988","journal-title":"Can J Psychiatry"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0278-5846(90)90071-N","article-title":"Neuroleptic-induced catatonia: neuroleptic malignant syndrome?","volume":"14","author":"de Leon","year":"1990","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000118713","article-title":"Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome?","volume":"23","author":"Kontaxakis","year":"1990","journal-title":"Neuropsychobiology"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00004583-199211000-00028","article-title":"Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome.","volume":"31","author":"Woodbury","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"suppl","key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2000-7671","article-title":"Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes.","volume":"33","author":"Dose","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-2001-18038","article-title":"Neuroleptic-induced pseudo-catatonia.","volume":"34","author":"Dose","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00004850-200411000-00007","article-title":"Aripiprazole and neuroleptic malignant syndrome.","volume":"19","author":"Chakraborty","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1592\/phco.2005.25.8.1156","article-title":"Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome.","volume":"25","author":"Tsai","year":"2005","journal-title":"Pharmacotherapy"},{"key":"R25-2-20210128","first-page":"79","article-title":"The neuroleptic malignant syndrome.","volume":"41","author":"Caroff","year":"1980","journal-title":"J Clin Psychiatry"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0447.1999.tb00980.x","article-title":"Catatonia under medication with risperidone in a 61-year-old patient.","volume":"99","author":"Bahro","year":"1999","journal-title":"Acta Psychiatr Scand"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0022-3565(25)39355-9","article-title":"On the relationship between D2 receptor density and neuroleptic-induced catalepsy among eight inbred strains of mice.","volume":"267","author":"Kanes","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.164.1.115","article-title":"Acute dystonic reactions complicated by psychotic phenomena.","volume":"164","author":"Thornton","year":"1994","journal-title":"Br J Psychiatry"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/00325481.1976.11708390","article-title":"Phenothiazine reaction simulating acute catatonia.","volume":"60","author":"Riley","year":"1976","journal-title":"Postgrad Med"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-0447.1996.tb09815.x","article-title":"Catatonia II. Treatment with lorazepam and electroconvulsive therapy.","volume":"38","author":"Bush","year":"1996","journal-title":"Acta Psychiatr Scand"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10401230009147094","article-title":"Catatonia in a psychiatric intensive care facility: incidence, and response to benzodiazapines.","volume":"12","author":"Lee","year":"2000","journal-title":"Ann Clin Psychiatry"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0010-440X(60)80013-2","article-title":"Experimental neurological syndromes and the new drug therapies in psychiatry.","volume":"1","author":"Deniker","year":"1960","journal-title":"Compr Psychiatry"},{"key":"R34-2-20210128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1192\/bjp.158.3.419","article-title":"Catatonia: harbinger of the neuroleptic malignant syndrome.","volume":"158","author":"White","year":"1991","journal-title":"Br J Psychiatry"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1192\/S0007125000141571","article-title":"Catatonia and neuroleptic malignant syndrome.","volume":"158","author":"White","year":"1991","journal-title":"Br J Psychiatry"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/15622970701287369","article-title":"Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine.","volume":"10","author":"Paparrigopoulos","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10401239409149013","article-title":"Malignant catatonia-a continuing reality.","volume":"6","author":"Singerman","year":"1994","journal-title":"Ann Clin Psychiatry"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.143.11.1374","article-title":"Lethal catatonia.","volume":"143","author":"Mann","year":"1986","journal-title":"Am J Psychiatry"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/00004583-199607000-00024","article-title":"Case study: neuroleptic malignant syndrome without pyrexia.","volume":"35","author":"Hynes","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R40-2-20210128","first-page":"75","article-title":"Recognising NMS as a type of catatonia.","volume":"8","author":"Fink","year":"1995","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"R41-2-20210128","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/j.1440-1614.2000.0822j.x","article-title":"Catatonic and non-catatonic neuroleptic malignant syndrome.","volume":"34","author":"Lee","year":"2000","journal-title":"Aust N Z J Psychiatry"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/10401230601163477","article-title":"Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome.","volume":"19","author":"Lee","year":"2007","journal-title":"Ann Clin Psychiatry"},{"key":"R43-2-20210128","first-page":"357","article-title":"Catatonic syndrome in a general hospital psychiatric population: frequency, clinical presentation, and response to lorazepam.","volume":"51","author":"Rosebush","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0447.1996.tb09814.x","article-title":"Catatonia I. Rating scale and standardized examination.","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatr Scand"},{"key":"R45-2-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0006-3223(98)00109-7","article-title":"Serum iron in catatonia and neuroleptic malignant syndrome.","volume":"44","author":"Lee","year":"1998","journal-title":"Biol Psychiatry"},{"key":"R47-2-20210128","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1176\/ajp.143.10.1227","article-title":"Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital.","volume":"143","author":"Pope","year":"1986","journal-title":"Am J Psychiatry"},{"key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome.","volume":"142","author":"Levenson","year":"1985","journal-title":"Am J Psychiatry"},{"key":"R53-2-20210128","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/j.1875-9114.1994.tb02851.x","article-title":"Treatment of acute neuroleptic-induced movement disorders.","volume":"14","author":"Tonda","year":"1994","journal-title":"Pharmacotherapy"},{"issue":"suppl 1","key":"R54-2-20210128","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/00002826-198300061-00008","article-title":"Amantadine in the management of extrapyramidal side effects.","volume":"6","author":"Borison","year":"1983","journal-title":"Clin Neuropharmacol"},{"key":"R55-2-20210128","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/jnnp.62.4.404","article-title":"Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine.","volume":"62","author":"Northoff","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R56-2-20210128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1176\/jnp.2007.19.4.406","article-title":"Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes.","volume":"19","author":"Carroll","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201002000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T15:10:35Z","timestamp":1739718635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201002000-00002"}},"subtitle":["Clinical Presentation, Response to Benzodiazepines, and Relationship to Neuroleptic Malignant Syndrome"],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181c9bfe6","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}